



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 23, 2012

Via E-mail

Mr. Brad Pyatt  
Chief Executive Officer  
MusclePharm Corporation  
5348 Vegas Dr.  
Las Vegas, NV 89108

**Re: MusclePharm Corporation  
Information Statement on Form PRE 14C  
Filed January 30, 2012  
File No. 000-53166**

Dear Mr. Pyatt:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler  
Assistant Director

cc: Joseph Lucosky  
Lucosky Brookman LLP  
33 Wood Avenue South, 6th Floor  
Iselin, NJ 08830